| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Bernardo L Wajchenberg | |
| P433 | issue | 2 | |
| P304 | page(s) | 187-218 | |
| P577 | publication date | 2007-03-12 | |
| P1433 | published in | Endocrine Reviews | Q3054007 |
| P1476 | title | beta-cell failure in diabetes and preservation by clinical treatment | |
| P478 | volume | 28 |
| Q36774879 | 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls |
| Q47814109 | 3D-Models of Insulin-Producing β-Cells: from Primary Islet Cells to Stem Cell-Derived Islets |
| Q50051445 | A Plant-Based Dietary Intervention Improves Beta-Cell Function and Insulin Resistance in Overweight Adults: A 16-Week Randomized Clinical Trial |
| Q38564721 | A Review of Diabetes Mellitus and Exposure to the Environmental Toxicant Cadmium with an Emphasis on Likely Mechanisms of Action |
| Q26799389 | A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond |
| Q82428933 | A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure |
| Q47240106 | A reappraisal on metformin |
| Q90058791 | A simple formula to correct for the effects of storage time and temperature on the insulin concentration |
| Q38740982 | A simple, reliable method for high-throughput screening for diabetes drugs using 3D β-cell spheroids |
| Q28568760 | Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication |
| Q51371120 | Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. |
| Q38197275 | Alogliptin benzoate for the treatment of type 2 diabetes |
| Q37794971 | Alogliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q36850046 | Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic β Cell Dysfunction |
| Q42798572 | Analysis of beta cell proliferation dynamics in zebrafish. |
| Q58789121 | Anemia is inversely associated with serum C-peptide concentrations in individuals with type 2 diabetes |
| Q28552543 | Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119 |
| Q92774095 | Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice |
| Q54571988 | Antidiabetic effects of Mukia maderaspatana and its phenolics: an in vitro study on gluconeogenesis and glucose uptake in rat tissues. |
| Q28075335 | Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis |
| Q33746847 | Assessment of re-aggregated human pancreatic islets for secondary drug screening |
| Q49241169 | Association between cadmium exposure and diabetes mellitus risk: a prisma-compliant systematic review and meta-analysis |
| Q34280152 | Bariatric surgery for type 2 diabetes |
| Q36272379 | Basic Fibroblast Growth Factor Inhibits Apoptosis and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients with Type 2 Diabetes by Reducing Cellular Oxidative Stress |
| Q36906173 | Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy |
| Q35951495 | Beta cell transplantation and immunosuppression: can't live with it, can't live without it. |
| Q37221767 | Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences. |
| Q37262812 | Beta-cell failure as a complication of diabetes |
| Q34117281 | Beta-cell specific deletion of Dicer1 leads to defective insulin secretion and diabetes mellitus. |
| Q37358990 | CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes |
| Q34654024 | CD3-specific antibodies: a portal to the treatment of autoimmunity |
| Q37654863 | Can Roux-en-Y gastric bypass provide a lifelong solution for diabetes mellitus? |
| Q33751570 | Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction |
| Q40970245 | Cell replacement and regeneration therapy for diabetes |
| Q36861224 | Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes |
| Q36418794 | Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin |
| Q35579114 | Clinical characteristics and beta cell function in Chinese patients with newly diagnosed type 2 diabetes mellitus with different levels of serum triglyceride |
| Q90835644 | Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus |
| Q41705110 | Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes |
| Q36705829 | Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer |
| Q46707968 | Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. |
| Q33610749 | Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy |
| Q36869489 | Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabete |
| Q43045655 | Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes |
| Q43769439 | Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). |
| Q37890790 | Control of postprandial glucose levels with insulin in type 2 diabetes |
| Q38211505 | Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study |
| Q36988161 | Correlation of serum homocysteine and previous history of gestational diabetes mellitus |
| Q35741902 | Cross-talks between microRNAs and mRNAs in pancreatic tissues of streptozotocin-induced type 1 diabetic mice |
| Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
| Q33850320 | Current status of glycemic control of patients with diabetes in Korea: the fifth Korea national health and nutrition examination survey |
| Q34374314 | Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus |
| Q47997151 | Depletion of Beta Cell Intranuclear Rodlets in Human Type II Diabetes. |
| Q38340349 | Depletion of intranuclear rodlets in mouse models of diabetes. |
| Q42446656 | Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes |
| Q41055915 | Development and assessment of the disposition index based on the oral glucose tolerance test in subjects with different glycaemic status. |
| Q35580004 | Development of a nongenetic mouse model of type 2 diabetes |
| Q38165184 | Diabetes and beta cell function: from mechanisms to evaluation and clinical implications |
| Q93364919 | Diabetes pharmacotherapy and effects on the musculoskeletal system |
| Q90918133 | Different roles of insulin receptor a and b in maintaining blood glucose homeostasis in zebrafish |
| Q37035092 | Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes? |
| Q37102846 | Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes? |
| Q37185954 | Does exercise have a role in the management of gestational diabetes mellitus? |
| Q43180130 | Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide |
| Q39206850 | Does the relief of glucose toxicity act as a mediator in proliferative actions of vanadium on pancreatic islet beta cells in streptozocin diabetic rats? |
| Q36424107 | Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial |
| Q35853171 | Early Pregnancy Maternal Lipid Profiles and the Risk of Gestational Diabetes Mellitus Stratified for Body Mass Index |
| Q35853273 | Early basal insulin therapy decreases new-onset diabetes after renal transplantation. |
| Q46854679 | Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients |
| Q57197955 | Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2 C95S) |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q51355147 | Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. |
| Q45067724 | Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric banding |
| Q40187492 | Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial |
| Q51175463 | Effect of exposure to non-esterified fatty acid on progressive deterioration of insulin secretion in patients with Type 2 diabetes: a long-term follow-up study. |
| Q46576386 | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. |
| Q51370472 | Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. |
| Q57494929 | Effectiveness of bariatric surgery in diabetes prevention in high-risk Asian individuals |
| Q41980574 | Effects of Extract from Solid-State Fermented Cordyceps sinensis on Type 2 Diabetes Mellitus |
| Q36310386 | Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study |
| Q36365237 | Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study |
| Q42493971 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes |
| Q51382768 | Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. |
| Q35179964 | Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes |
| Q33804747 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin |
| Q33844182 | Effects of high-fat diet and fructose-rich diet on obesity, dyslipidemia and hyperglycemia in the WBN/Kob-Leprfa rat, a new model of type 2 diabetes mellitus |
| Q34594675 | Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes |
| Q33751560 | Effects of intravenous glucose load on insulin secretion in patients with ketosis-prone diabetes during near-normoglycemia remission |
| Q86582910 | Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes |
| Q48031376 | Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period |
| Q33607742 | Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus |
| Q34044817 | Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study |
| Q44120755 | Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. |
| Q58700185 | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial |
| Q35228228 | Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus |
| Q35214435 | Enhanced glycemic control with combination therapy for type 2 diabetes in primary care |
| Q64124562 | Evaluation of the association between urinary cadmium levels below threshold limits and the risk of diabetes mellitus: a dose-response meta-analysis |
| Q36716120 | Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes |
| Q33591271 | Evidence-based clinical use of insulin premixtures |
| Q90178371 | Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas |
| Q47991877 | Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice |
| Q64941368 | Exendin-4 protects INS-1 cells against palmitate-induced apoptosis through the IRE1α-Xbp1 signaling pathway. |
| Q40667176 | FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents |
| Q64884015 | Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes. |
| Q37835612 | Focus on incretin-based therapies: targeting the core defects of type 2 diabetes |
| Q34132215 | FoxM1 is up-regulated by obesity and stimulates beta-cell proliferation |
| Q37900151 | From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy |
| Q36402230 | Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist. |
| Q42477270 | Gastric Band Surgery Leads to Improved Insulin Secretion in Overweight People with Type 2 Diabetes |
| Q86039713 | Genetic deletion of Wdr13 improves the metabolic phenotype of Lepr (db/db) mice by modulating AP1 and PPARγ target genes |
| Q38249061 | Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis |
| Q36853698 | Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum |
| Q37921903 | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? |
| Q37403983 | Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). |
| Q92932433 | Hepatic stress associated with pathologies characterized by disturbed glucose production |
| Q33890987 | High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis |
| Q34425147 | High glucose predisposes gene expression and ERK phosphorylation to apoptosis and impaired glucose-stimulated insulin secretion via the cytoskeleton |
| Q39629784 | Hydrogen sulphide protects mouse pancreatic β‐cells from cell death induced by oxidative stress, but not by endoplasmic reticulum stress |
| Q38108757 | Imaging beta-cell mass and function in situ and in vivo. |
| Q34099969 | Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? |
| Q89477060 | Impact of acute-phase insulin secretion on glycemic variability in insulin-treated patients with type 2 diabetes |
| Q48277301 | Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study |
| Q43247403 | Impact of plasmatic lipids in glycemic control and its influence in the cardiometabolic risk in morbidly obese subjects |
| Q35034772 | Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis |
| Q51011931 | Impaired muscarinic type 3 (M3) receptor/PKC and PKA pathways in islets from MSG-obese rats. |
| Q38341934 | Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases |
| Q44598061 | Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control |
| Q35043408 | In vivo conditional Pax4 overexpression in mature islet β-cells prevents stress-induced hyperglycemia in mice |
| Q27320049 | In vivo screening for secreted proteins that modulate glucose handling identifies interleukin-6 family members as potent hypoglycemic agents |
| Q36861083 | Increase in Insulin Secretion Induced by Panax ginseng Berry Extracts Contributes to the Amelioration of Hyperglycemia in Streptozotocininduced Diabetic Mice |
| Q36194286 | Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy |
| Q37280699 | Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes |
| Q37198836 | Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus |
| Q35760283 | Incretin therapy--present and future |
| Q51456897 | Incretin-based Therapies for Type 2 Diabetes. |
| Q34699191 | Incretin-based therapies in prediabetes: Current evidence and future perspectives |
| Q42578569 | Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus |
| Q34787014 | Inflammation of the hypothalamus leads to defective pancreatic islet function. |
| Q34381400 | Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. |
| Q37209420 | Influence of islet function on typing and prognosis of new-onset diabetes after intensive insulin therapy |
| Q37290387 | Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs |
| Q37227907 | Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs |
| Q37505840 | Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies |
| Q64904305 | Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. |
| Q33607759 | Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial |
| Q81157739 | Insulin may have a role to play in protecting beta cells from deterioration in diabetes |
| Q37598881 | Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes |
| Q43056051 | Insulin secretion and impaired glucose tolerance |
| Q36938045 | Insulin secretion enhancing activity of roselle calyx extract in normal and streptozotocin-induced diabetic rats |
| Q35995444 | Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa |
| Q85298842 | Insulin therapy for type 2 diabetes |
| Q54353931 | Insulin therapy improves islet functions by restoring pancreatic vasculature in high-fat diet-fed streptozotocin-diabetic rats. |
| Q44910855 | Insulin treatment of type 2 diabetes: considerations when converting from human insulin to insulin analogs |
| Q38875279 | Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage |
| Q53130900 | Interaction of herbal compounds with biological targets: a case study with berberine. |
| Q39484862 | Involvement of P2X receptors in the regulation of insulin secretion, proliferation and survival in mouse pancreatic β-cells |
| Q33880174 | Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis |
| Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
| Q33850316 | It's Still Not Too Late to Make a Change: Current Status of Glycemic Control in Korea |
| Q36700877 | Leptin therapy, insulin sensitivity, and glucose homeostasis. |
| Q33846858 | Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes |
| Q34054232 | Lessons from models of pancreatic beta cells for engineering glucose-sensing cells |
| Q38078436 | Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation |
| Q33785308 | Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. |
| Q38884947 | Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model |
| Q34115152 | Loss of AMP-activated protein kinase alpha2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia. |
| Q51324898 | Management of a prediabetes case with the DPP-4 inhibitor sitagliptin. |
| Q37894446 | Management of type 2 diabetes: new and future developments in treatment |
| Q37941683 | Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus |
| Q55155260 | Metformin Inhibits Mouse Islet Insulin Secretion and Alters Intracellular Calcium in a Concentration-Dependent and Duration-Dependent Manner near the Circulating Range. |
| Q37110636 | MicroRNA-24/MODY gene regulatory pathway mediates pancreatic β-cell dysfunction |
| Q52689330 | Modeling human pancreatic beta cell dedifferentiation. |
| Q37777880 | Modulation of Ingestive Behavior and Gastrointestinal Motility by Ghrelin in Diabetic Animals and Humans |
| Q28081094 | Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus |
| Q33619580 | Muscarinic control of MIN6 pancreatic β cells is enhanced by impaired amino acid signaling. |
| Q37921910 | New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms |
| Q39881169 | Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. |
| Q35645893 | Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment |
| Q33323030 | Noninvasive in vivo imaging of pancreatic islet cell biology |
| Q34431018 | Noopept normalizes parameters of the incretin system in rats with experimental diabetes. |
| Q37960149 | Novel GLP-1 receptor agonists for diabetes |
| Q34708337 | Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q83782939 | Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes |
| Q37954693 | Obesity and type 2 diabetes: which patients are at risk? |
| Q36783740 | Obesity, autoimmunity, and double diabetes in youth |
| Q27021446 | On ceramides, other sphingolipids and impaired glucose homeostasis |
| Q35260937 | Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. |
| Q39787095 | Optimization of GPR40 Agonists for Type 2 Diabetes. |
| Q21198761 | Oral Insulin |
| Q48203947 | Oral insulin delivery: existing barriers and current counter-strategies |
| Q42326757 | Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. |
| Q37060691 | Overexpression of pre-pro-cholecystokinin stimulates beta-cell proliferation in mouse and human islets with retention of islet function |
| Q38128788 | Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes |
| Q37280479 | PTB and TIAR binding to insulin mRNA 3'- and 5'UTRs; implications for insulin biosynthesis and messenger stability |
| Q38784851 | Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in db/db Mice |
| Q52575777 | Pancreatic Aquaporin-7: A Novel Target for Anti-diabetic Drugs? |
| Q41054906 | Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy |
| Q30708894 | Pancreatic β-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function |
| Q38951177 | Pancreatic β-cell identity in diabetes. |
| Q37611922 | Pdx1 and other factors that regulate pancreatic beta-cell survival |
| Q37194756 | Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. |
| Q92491956 | Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus |
| Q37641326 | Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog |
| Q35895868 | Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control |
| Q34070530 | Postprandial oxidative stress and gastrointestinal hormones: is there a link? |
| Q38749204 | Potential efficacy of Lactobacillus casei IBRC_M10711 on expression and activity of insulin degrading enzyme but not insulin degradation. |
| Q89475403 | Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site |
| Q90025604 | Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes |
| Q33628631 | Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q57189912 | Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells |
| Q36740436 | Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions |
| Q43171502 | Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo. |
| Q42460121 | Quantification of the relationship between glycemia and beta-cell mass adaptation in vivo |
| Q37056832 | Quantification of β-cell insulin secretory function using a graded glucose infusion with C-peptide deconvolution in dysmetabolic, and diabetic cynomolgus monkeys |
| Q34887952 | Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus |
| Q27317203 | Reduction of connexin36 content by ICER-1 contributes to insulin-secreting cells apoptosis induced by oxidized LDL particles |
| Q37603286 | Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q37650996 | Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies |
| Q37288637 | Role of nucleolar protein NOM1 in pancreatic islet β cell apoptosis in diabetes |
| Q42759245 | Rosiglitazone as an option for patients with acromegaly: a case series |
| Q84218905 | Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study |
| Q33661359 | Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies |
| Q37082630 | Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults |
| Q36807640 | Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice |
| Q36711136 | Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. |
| Q38038662 | Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q38195430 | Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis |
| Q37703202 | Sitagliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q91991896 | Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes |
| Q42374211 | Sodium fluorocitrate having protective effect on palmitate-induced beta cell death improves hyperglycemia in diabetic db/db mice |
| Q35849373 | Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. |
| Q65001183 | Sonodynamic therapy inhibits palmitate-induced beta cell dysfunction via PINK1/Parkin-dependent mitophagy. |
| Q34575201 | Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor |
| Q41812480 | Stimulation of insulin secretion by large-dose oral arginine administration in healthy adults |
| Q30300205 | Stress-induced dissociations between intracellular calcium signaling and insulin secretion in pancreatic islets |
| Q41766825 | Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide |
| Q54985686 | Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. |
| Q37247487 | Synaptotagmins bind calcium to release insulin. |
| Q38259937 | Systematic review of feline diabetic remission: separating fact from opinion |
| Q38254279 | Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions |
| Q37900307 | Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q38181087 | Th17 cells in immunity and autoimmunity. |
| Q37760873 | The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach |
| Q34102119 | The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients |
| Q28576337 | The diabetogenic effects of excessive ethanol: reducing beta-cell mass, decreasing phosphatidylinositol 3-kinase activity and GLUT-4 expression in rats |
| Q33849176 | The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo |
| Q41689708 | The dynamic plasticity of insulin production in β-cells. |
| Q38442291 | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. |
| Q51013418 | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. |
| Q33569142 | The metabolic syndrome |
| Q35760288 | The role of incretin therapy at different stages of diabetes |
| Q37024780 | The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities |
| Q64066210 | The role of membrane excitability in pancreatic β-cell glucotoxicity |
| Q39153152 | The undoing and redoing of the diabetic β-cell |
| Q37377618 | Therapeutic Strategies to Increase Human β-Cell Growth and Proliferation by Regulating mTOR and GSK-3/β-Catenin Pathways |
| Q36783865 | Therapy in the early stage: incretins |
| Q51158595 | Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. |
| Q38441421 | Treating posttransplantation diabetes mellitus |
| Q41480944 | Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality |
| Q34620430 | Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies |
| Q48233504 | Type 2 diabetes: Does pancreatic fat really matter? |
| Q42597241 | Unusually rapid beta-cell failure in a patient newly diagnosed with type 2 diabetes presenting acutely with unprovoked severe hyperglycaemic hyperosmolar state: a case report |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
| Q37313418 | Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. |
| Q85887622 | Visceral adiposity index and insulin secretion and action in first-degree relatives of subjects with type 2 diabetes |
| Q92197404 | What role do fat cells play in pancreatic tissue? |
| Q38951181 | When β-cells fail: lessons from dedifferentiation |
| Q27316605 | Whole organism high content screening identifies stimulators of pancreatic beta-cell proliferation |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
| Q24630175 | miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression |
| Q42535316 | β-cell preservation and regeneration for diabetes treatment: where are we now? |
Search more.